Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05727540
NCT05727540CompletedNot Applicable

The Cohort Study of Uveitis Patients Based on Real-world Data

Zhongshan Ophthalmic Center, Sun Yat-sen University2 sites in 1 country300 target enrollmentStarted: February 20, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
300
Locations
2
Primary Endpoint
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion Criteria

  • •Uveitis during the first month after any intraocular surgery; <18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Arms & Interventions

Infectious uveitis

Noninfectious uveitis

Outcomes

Primary Outcomes

The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

Time Frame: 12 months post-treatment

activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

Time Frame: 12 months post-treatment

inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

Secondary Outcomes

  • Best corrected visual acuity(1 month post-treatment)
  • Best corrected visual acuity(3 months post-treatment)
  • Best corrected visual acuity(6 months post-treatment)
  • Best corrected visual acuity(12 months post-treatment)
  • Best corrected visual acuity(24 months post-treatment)
  • The number of intraocular pressure(1 month post-treatment)
  • The number of intraocular pressure(3 months post-treatment)
  • The number of Intraocular pressure(12 months post-treatment)
  • The number of Intraocular pressure(24 months post-treatment)
  • Central retinal thickness(1 month post-treatment)
  • Central retinal thickness(3 months post-treatment)
  • Central retinal thickness(6 months post-treatment)
  • Central retinal thickness(12 months post-treatment)
  • Central retinal thickness(24 months post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(1 month post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(3 months post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(6 months post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(24 months post-treatment)
  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions(3 months post-treatment)
  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions(6 months post-treatment)
  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions(24 months post-treatment)
  • The number of intraocular pressure(6 months post-treatment)
  • The number of Intraocular pressure(36 months post-treatment)
  • Central retinal thickness(36 months post-treatment)
  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions(36 months post-treatment)
  • Best corrected visual acuity(36 months post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(36 months post-treatment)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Epidemiology and Clinical Features of Uveitis in a Tertiary ReferralUveitis
NCT03646890University Hospital, Montpellier985
Recruiting
Not Applicable
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric AgeUveitis
NCT06273748Meyer Children's Hospital IRCCS290
Completed
Not Applicable
Clinical Outcome in UveitisUveitis
NCT01983488Moorfields Eye Hospital NHS Foundation Trust231
Completed
Not Applicable
Evaluation and Treatment of Patients With Inflammatory Eye DiseasesIridocyclitisRetinal DiseaseChoroiditisIritis
NCT00006188National Eye Institute (NEI)300
Recruiting
Not Applicable
Lyon Uveitis StudyUveitis
NCT03877575Hospices Civils de Lyon750